Table 3.
Sunitinib (n = 27)a | Sorafenib (n = 4) | |
---|---|---|
Macrocytosis resolved while on therapy with tyrosine kinase inhibitor | 37% | 75% |
Macrocytosis resolved during follow‐up | 100% | 100% |
Median time to resolution after stopping therapy | 1 m | 0 m |
Missing follow‐up information for 4/31 patient patients that explains n = 27.